Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort

Background Merkel cell carcinoma (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor avelumab has shown high response rates (RRs) and durable responses in patients with advanced MCC (aMCC) in clinical trials. To date, o...

Full description

Saved in:
Bibliographic Details
Main Authors: Sonja Levy, Dirk Grünhagen, Maureen J B Aarts, Ferry A L M Eskens, Kristien B M I Keymeulen, Lukas B Been, Alexander van Akkooi, Mathilde Jalving, Margot E T Tesselaar
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001076.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items